|
[1]
|
Peer R, Shabir N. Iatrogenesis: a review on nature, extent, and distribution of healthcare hazards. J Fam Med Primary Care 2018;7(2):309 − 14. http://dx.doi.org/10.4103/jfmpc.jfmpc_329_17CrossRef
|
|
[2]
|
Shamna M, Dilip C, Ajmal M, Linu Mohan P, Shinu C, Jafer CP, et al. A prospective study on adverse drug reactions of antibiotics in a tertiary care hospital. Saudi Pharm J 2014;22(4):303 − 8. http://dx.doi.org/10.1016/j.jsps.2013.06.004CrossRef
|
|
[3]
|
WHO. The Montreux Charter on Patient Safety galvanizes action to address avoidable harm in health care. 2023. https://www.who.int/news/item/28-02-2023-the-montreux-charter-on-patient-safety-galvanizes-action-to-address-avoidable-harm-in-health-care. [2023-4-20].https://www.who.int/news/item/28-02-2023-the-montreux-charter-on-patient-safety-galvanizes-action-to-address-avoidable-harm-in-health-care |
|
[4]
|
WHO Meeting on International Drug Monitoring: the Role of National Centres (1971: Geneva, Switzerland), World Health Organization. International drug monitoring: the role of national centres, report of a WHO meeting [held in Geneva from 20 to 25 September 1971]. World Health Organization. 1972. https://apps.who.int/iris/handle/10665/40968. [2023-4-20].https://apps.who.int/iris/handle/10665/40968 |
|
[5]
|
Verma R, Vasudevan B, Pragasam V. Severe cutaneous adverse drug reactions. Med J Armed Forces India 2013;69(4):375 − 83. http://dx.doi.org/10.1016/j.mjafi.2013.01.007CrossRef
|
|
[6]
|
WHO. WHO calls for urgent action by countries for achieving medication without harm. 2022. https://www.who.int/news/item/16-09-2022-who-calls-for-urgent-action-by-countries-for-achieving-medication-without-harm. [2023-4-20].https://www.who.int/news/item/16-09-2022-who-calls-for-urgent-action-by-countries-for-achieving-medication-without-harm |
|
[7]
|
Onder G, Van Der Cammen T J M, Petrovic M, Somers A, Rajkumar C. Strategies to reduce the risk of iatrogenic illness in complex older adults. Age Ageing 2013;42(3):284 − 91. http://dx.doi.org/10.1093/ageing/aft038CrossRef
|
|
[8]
|
Ligi I, Arnaud F, Jouve E, Tardieu S, Sambuc R, Simeoni U. Iatrogenic events in admitted neonates: a prospective cohort study. Lancet 2008;371(9610):404 − 10. http://dx.doi.org/10.1016/S0140-6736(08)60204-4CrossRef
|
|
[9]
|
Palmieri PA, Peterson LT, Ford EW. Technological iatrogenesis: new risks force heightened management awareness. J Healthcare Risk Manage 2007;27(4):19 − 24. http://dx.doi.org/10.1002/jhrm.5600270405CrossRef
|
|
[10]
|
Mathioudakis NN, Abusamaan MS, Shakarchi AF, Sokolinsky S, Fayzullin S, McGready J, et al. Development and validation of a machine learning model to predict near-term risk of iatrogenic hypoglycemia in hospitalized patients. JAMA Network Open 2021;4(1):e2030913. http://dx.doi.org/10.1001/jamanetworkopen.2020.30913CrossRef
|
|
[11]
|
Sanfilippo S, Michaud V, Wei JQ, Bikmetov R, Turgeon J, Brunetti L. Classification and assessment of medication risk in the elderly (Care): use of a medication risk score to inform patients’ readmission likelihood after hospital discharge. J Clin Med 2021;10(17):3947. http://dx.doi.org/10.3390/jcm10173947CrossRef
|
|
[12]
|
Franck LS, Scoppettuolo LA, Wypij D, Curley MAQ. Validity and generalizability of the Withdrawal Assessment Tool-1 (WAT-1) for monitoring iatrogenic withdrawal syndrome in pediatric patients. Pain 2012;153(1):142 − 8. http://dx.doi.org/10.1016/j.pain.2011.10.003CrossRef
|
|
[13]
|
Abdouni R, Reyburn-Orne T, Youssef TH, Haddad IY, Gerkin RD. Impact of a standardized treatment guideline for pediatric iatrogenic opioid dependence: a quality improvement initiative. J Pediatr Pharmacol Ther 2016;21(1):54 − 65. http://dx.doi.org/10.5863/1551-6776-21.1.54CrossRef
|
|
[14]
|
Scott IA, Gray LC, Martin JH, Mitchell CA. Minimizing inappropriate medications in older populations: a 10-step conceptual framework. Am J Med 2012;125(6):529 − 37.e4. http://dx.doi.org/10.1016/j.amjmed.2011.09.021CrossRef
|
|
[15]
|
Schwappach DLB, Wernli M. Medication errors in chemotherapy: incidence, types and involvement of patients in prevention. A review of the literature. Eur J Cancer Care 2010;19(3):285 − 92. http://dx.doi.org/10.1111/j.1365-2354.2009.01127.xCrossRef
|
|
[16]
|
Hernandez SE, Conrad DA, Marcus-Smith MS, Reed P, Watts C. Patient-centered innovation in health care organizations. A conceptual framework and case study application. Health Care Manage Rev 2013;38(2):166 − 75. http://dx.doi.org/10.1097/HMR.0b013e31825e718aCrossRef
|
|
[17]
|
WHO. Protecting the health workers who protect us all. 2020. https://www.who.int/news-room/feature-stories/detail/protecting-the-health-workers-who-protect-us-all. [2023-4-20].https://www.who.int/news-room/feature-stories/detail/protecting-the-health-workers-who-protect-us-all |
|
[18]
|
World Health Organization. The safety of medicines in public health programmes: pharmacovigilance, an essential tool. World Health Organization. 2006. https://apps.who.int/iris/handle/10665/43384.[2023-4-20].https://apps.who.int/iris/handle/10665/43384.[2023-4-20] |
|
[19]
|
OECD. OECD Oslo manual 3rd edition, 2005. [2023-4-20]. |
|
[20]
|
Instruction n°DGOS/PF4/2014/33 du 28 janvier 2014 relative au programme de recherche translationnelle, au programme hospitalier de recherche clinique, au programme de recherche médico-économique, au programme de recherche sur la performance du système de soins, au programme de recherche infirmière et paramédicale. http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=37900. [2023-4-20].http://circulaire.legifrance.gouv.fr/index.php?action=afficherCirculaire&hit=1&r=37900 |
|
[21]
|
Dubromel A, Geffroy L, Aulagner G, Dussart C. Assessment and diffusion of medical innovations in France: an overview. J Mark Access Health Policy 2018;6(1):1458575. http://dx.doi.org/10.1080/20016689.2018.1458575CrossRef
|
|
[22]
|
Greenwood JC. The value of saving lives: policies for patient access to life-saving therapies must keep pace with biomedical innovation. Pharm Technol 2016;40(5):12. https://www.biopharminternational.com/view/image-analysis-algorithm-for-therapeutic-mab-aggregate-analysis.https://www.biopharminternational.com/view/image-analysis-algorithm-for-therapeutic-mab-aggregate-analysis |
|
[23]
|
Lichtenberg FR. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000-2009. 2012. https://www.nber.org/papers/w18235. [2023-4-20].https://www.nber.org/papers/w18235 |